Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 2/20 | 0.53 |
| ▸ | RET | P07949 | 5/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.45 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.44 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.44 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 1/20 | 0.44 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21634344 | 0.85 | TNIK (0.44) | MET | |
| SCHEMBL22118652 | 0.79 | RET (0.61) | RET | |
| SCHEMBL16268184 | 0.79 | MET (0.51) | METRETCCNCCDK8GPR119 | |
| SCHEMBL15416477 | 0.79 | DDB1 (0.53) | METCCNCCDK8GPR119DDB1 | |
| SCHEMBL15416435 | 0.79 | MET (0.53) | METRETCCNCCDK8GPR119 | |
| SCHEMBL29341045 | 0.79 | RET (0.58) | RET | |
| SCHEMBL15884624 | 0.79 | MET (0.58) | METCCNCCDK8GPR119DDB1 | |
| SCHEMBL24257732 | 0.79 | CCNC (0.49) | METRETCCNCCDK8GPR119 | |
| SCHEMBL30452665 | 0.79 | CCNC (0.49) | METRETCCNCCDK8GPR119 | |
| SCHEMBL29341043 | 0.79 | RET (0.60) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195467-B2 | Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient | JBKLAB CO., LTD. (KR) | 2025-01-14 | — | — | US | disclosed |
| EP-3819298-B1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | JBKLAB CO LTD (KR) | 2024-10-30 | — | — | EP | disclosed |
| CN-112533919-B | Compounds having TRKA inhibitory activity and pharmaceutical compositions for preventing or treating pain comprising the same as active ingredient | 株式会社张峰根硏究所 | 2023-06-16 | — | — | CN | disclosed |
| US-20210309665-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | JBKLAB CO., LTD (KR) | 2021-10-07 | — | — | US | disclosed |
| US-20210309665-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | JBKLAB CO., LTD (KR) | 2021-10-07 | — | — | US | disclosed |
| EP-3819298-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | Oncopharmatech Inc. (KR) | 2021-05-12 | — | — | EP | disclosed |
| CN-112533919-A | Compound having TRKA inhibitory activity and pharmaceutical composition for preventing or treating pain comprising the same as active ingredient | 昂科制药技术公司 | 2021-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195467-B2 | Compound having TrkA inhibitory activity and pharmaceutical composition, for preventing or alleviating pain, containing same as active ingredient | NGF, OPRL1, TRPV1 | MET 2073/4885RET 127/4885NR1H2 2591/4885 |
| US-20210309665-A1 | COMPOUND HAVING TRKA INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION, FOR PREVENTING OR ALLEVIATING PAIN, CONTAINING SAME AS ACTIVE INGREDIENT | NGF, OPRL1, TRPV1 | MET 2073/4885RET 127/4885NR1H2 2591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.